- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03284567
Football Fitness After Breast Cancer (FFABC)
A Randomized Controlled Trial to Investigate the Health Promoting Effects of a Football Fitness Intervention for Women After Treatment for Breast Cancer
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Copenhagen, Danemark, 2100
- University Hospital of Copenhagen, Rigshospitalet
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Women surgically managed for breast cancer, local and regional advanced breast cancer.
- Completion of adjuvant chemotherapy and radiation therapy.
- Legally competent persons with ability to read and understand Danish.
- Signed informed consent.
- Performance level 0-1 (WHO).
Exclusion Criteria:
- WHO performance level > 1.
- Osteoporosis (T-score < -2.5).
- Known metastatic breast cancer (stage IV).
- Women in DBCG-group I (age => 60 years, tumor =< 10 mm, invasive ductal carcinoma grade I, invasive lobular carcinoma grade I / II, estrogen receptor positive and HER2 normal).
- Cardiovascular or pulmonary disorders (e.g., arrhythmias, ischemic heart disease, unregulated high blood pressure, chronic obstructive lung disease).
- Ongoing anticoagulant therapy (vitamin K antagonists; Marevan, Marcoumar and low molecular weight heparins; Innohep, Clexane, Fragmin) for pulmonary embolism or deep venous thrombosis (DVT) due to increased bleeding risk of falls and clashes with other players during exercise.
- Current or scheduled chemotherapy and radiation therapy in the intervention period (12 months).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Football fitness
Participants in the intervention group will practice soccer for 52 weeks two times weekly. A soccer instructor will be in charge of all training sessions. The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games. Training will take place on a natural grass pitch. In adverse weather conditions (i.e., < 5°C or heavy rain) training will be performed indoors. Participants will be told to avoid hard tackles and other actions that carry a risk of injury. |
The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games. Training will take place on a natural grass pitch. In adverse weather conditions (i.e., < 5°C or heavy rain) training will be performed indoors |
|
Aucune intervention: Control group
Participants in the control group will receive verbal advice about the benefits of exercise and physical activity.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean change in fitness level (maximal oxygen uptake) from baseline to month 6 and month 12.
Délai: 6 months and 12 months.
|
Incremental test to exhaustion on a cycle ergometer.
|
6 months and 12 months.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean change in whole-body fat mass from baseline to month 6 and month 12.
Délai: 6 months and 12 months.
|
Assessed by dual energy x-ray absorptiometry.
|
6 months and 12 months.
|
|
Mean change in whole-body weight from baseline to month 6 and month 12.
Délai: 6 month and 12 month.
|
Body weight was measured with a digital platform scale.
|
6 month and 12 month.
|
|
Mean change in whole-body muscle mass from baseline to month 6 and month 12.
Délai: 6 month and 12 month.
|
Assessed by dual energy x-ray absorptiometry.
|
6 month and 12 month.
|
|
Mean change in muscle strength from baseline to month 6 and month 12.
Délai: 6 month and 12 month.
|
Dynamic concentric muscle strength for the knee extensors (1RM).
|
6 month and 12 month.
|
|
Mean change in balance from baseline to month 6 and month 12.
Délai: 6 month and 12 month.
|
Single-leg flamingo balance test.
|
6 month and 12 month.
|
|
Mean change in blood pressure from baseline to month 6 and month 12.
Délai: 6 month and 12 month.
|
Blood pressure will be measured with a digital sphygmomanometer.
|
6 month and 12 month.
|
|
Mean change in markers of bone mineral metabolism from baseline to month 6 and month 12.
Délai: 6 month and 12 month.
|
Procollagen type I C propeptide, osteocalcin and C-terminal telopeptide will be analyzed by a chemiluminescence method using a fully automated immunoassay system (iSYS, Immunodiagnostic Systems Ltd., Boldon, England.
|
6 month and 12 month.
|
|
Mean change in cholesterol from baseline to month 6 and month 12.
Délai: 6 month and 12 month.
|
Blood samples will be analyzed at baseline, 6 and 12 month for total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and glycosylated hemoglobin, respectively, by automated analyzers (Cobas Fara, Roche, Neuilly sur Seine, France) using enzymatic kits (Roche Diagnostics, Mannheim, Germany, and Tosoh G7, Tosoh Europe, Tessenderlo, Belgium).
|
6 month and 12 month.
|
|
Self-reported physical activity from baseline to month 6 and month 12.
Délai: 6 month and 12 month.
|
Assessed by the International Physical Activity Questionnaire (IPAQ).
|
6 month and 12 month.
|
|
Self-reported diagnosis-specific symptoms and side-effects from baseline to month 6 and month 12.
Délai: 6 month and 12 month.
|
Assessed by the supplement EORTC QLQ-BR23.
|
6 month and 12 month.
|
|
Self-reported health-related quality of life outcomes from baseline to month 6 and month 12.
Délai: 6 month and 12 month.
|
Assessed by the 15 subscales of the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30).
|
6 month and 12 month.
|
|
Self-reported functional level in upper extremities from baseline to month 6 and month 12.
Délai: 6 month and 12 month.
|
Assessed by disabilities of the arm, shoulder and hand (DASH).
|
6 month and 12 month.
|
|
Self-reported health related quality of life from baseline to month 6 and month 12.
Délai: 6 month and 12 month.
|
Assessed by The Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36)
|
6 month and 12 month.
|
|
Mean change in bone mineral density (BMD) of the spine (L2-L4), Total hip and Femoral Neck.
Délai: 6 month and 12 month.
|
Assessed by dual energy x-ray absorptiometry.
|
6 month and 12 month.
|
|
Mean change in total body and leg bone mineral content (BMC).
Délai: 6 month and 12 month.
|
Assessed by dual energy x-ray absorptiometry.
|
6 month and 12 month.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Publications et liens utiles
Publications générales
- Bloomquist K, Krustrup P, Fristrup B, Sorensen V, Helge JW, Helge EW, Soelberg Vadstrup E, Rorth M, Hayes SC, Uth J. Effects of football fitness training on lymphedema and upper-extremity function in women after treatment for breast cancer: a randomized trial. Acta Oncol. 2021 Mar;60(3):392-400. doi: 10.1080/0284186X.2020.1868570. Epub 2021 Jan 11.
- Uth J, Fristrup B, Sorensen V, Helge EW, Christensen MK, Kjaergaard JB, Moller TK, Mohr M, Helge JW, Jorgensen NR, Rorth M, Vadstrup ES, Krustrup P. Exercise intensity and cardiovascular health outcomes after 12 months of football fitness training in women treated for stage I-III breast cancer: Results from the football fitness After Breast Cancer (ABC) randomized controlled trial. Prog Cardiovasc Dis. 2020 Nov-Dec;63(6):792-799. doi: 10.1016/j.pcad.2020.08.002. Epub 2020 Aug 12.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- FFABC
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Tumeur mammaire Femme
-
Jiangsu HengRui Medicine Co., Ltd.RecrutementHER2-positif Primary Breast Cancer Cancer participants atteints d'une maladie invasive résiduelle après un traitement néoadjuvantChine
-
AstraZenecaActif, ne recrute pasAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerÉtats-Unis, France, Royaume-Uni, Corée du Sud